Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

Courtney D. DiNardo, Gail J. Roboz, Justin M. Watts, Yazan F. Madanat, Gabrielle T. Prince, Praneeth Baratam, Stéphane de Botton, Anthony Stein, James M. Foran, Martha L. Arellano, David A. Sallman, Mohammad Hossain, Dylan M. Marchione, Xiaofei Bai, Prapti A. Patel, Stephanie M. Kapsalis, Guillermo Garcia-Manero, Amir T. Fathi

Blood Adv (2024) 8 (15): 4209–4220.

https://doi.org/10.1182/bloodadvances.2023012302

Published: 2024

Includes: Supplemental data

Journal Articles

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Alex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, Kelly S. Chien, Samuel Urrutia, Alexandre Bazinet, Juan Jose Rodriguez-Sevilla, Danielle Hammond, Koji Sasaki, Koichi Takahashi, Courtney D. DiNardo, Farhad Ravandi, Gautam Borthakur, Tapan M. Kadia, Rashmi Kanagal-Shamanna, Hagop M. Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo

Blood Adv (2024) 8 (11): 2695–2706.

https://doi.org/10.1182/bloodadvances.2024012565

Published: 2024

Includes: Supplemental data

Journal Articles

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials

Pau Montesinos, Amir T. Fathi, Stéphane de Botton, Eytan M. Stein, Amer M. Zeidan, Yue Zhu, Thomas Prebet, Carlos E. Vigil, Iryna Bluemmert, Xin Yu, Courtney D. DiNardo

Blood Adv (2024) 8 (10): 2509–2519.

https://doi.org/10.1182/bloodadvances.2023011914

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Alex Bataller, Alexandre Bazinet, Courtney D. DiNardo, Abhishek Maiti, Gautam Borthakur, Naval G. Daver, Nicholas J. Short, Elias J. Jabbour, Ghayas C. Issa, Naveen Pemmaraju, Musa Yilmaz, Guillermo Montalban-Bravo, Koichi Takahashi, Sanam Loghavi, Guillermo Garcia-Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia

Blood Adv (2024) 8 (4): 927–935.

https://doi.org/10.1182/bloodadvances.2023011757

Published: 2024

Includes: Supplemental data

Journal Articles

Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1 , GATA2 , and DDX41

Claire C. Homan, Michael W. Drazer, Kai Yu, David M. Lawrence, Jinghua Feng, Luis Arriola-Martinez, Matthew J. Pozsgai, Kelsey E. McNeely, Thuong Ha, Parvathy Venugopal, Peer Arts, Sarah L. King-Smith, Jesse Cheah, Mark Armstrong, Paul Wang, Csaba Bödör, Alan B. Cantor, Mario Cazzola, Erin Degelman, Courtney D. DiNardo, Nicolas Duployez, Remi Favier, Stefan Fröhling, Ana Rio-Machin, Jeffery M. Klco, Alwin Krämer, Mineo Kurokawa, Joanne Lee, Luca Malcovati, Neil V. Morgan, Georges Natsoulis, Carolyn Owen, Keyur P. Patel, Claude Preudhomme, Hana Raslova, Hugh Rienhoff, Tim Ripperger, Rachael Schulte, Kiran Tawana, Elvira Velloso, Benedict Yan, Erika Kim, Raman Sood, Amy P. Hsu, Steven M. Holland, Kerry Phillips, Nicola K. Poplawski, Milena Babic, Andrew H. Wei, Cecily Forsyth, Helen Mar Fan, Ian D. Lewis, Julian Cooney, Rachel Susman, Lucy C. Fox, Piers Blombery, Deepak Singhal, Devendra Hiwase, Belinda Phipson, Andreas W. Schreiber, Christopher N. Hahn, Hamish S. Scott, Paul Liu, Lucy A. Godley, Anna L. Brown

Blood Adv (2023) 7 (20): 6092–6107.

https://doi.org/10.1182/bloodadvances.2023010045

Published: 2023

Includes: Supplemental data

Journal Articles

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Blood Adv (2023) 7 (14): 3573–3581.

https://doi.org/10.1182/bloodadvances.2022009632

Published: 2023

Includes: Supplemental data

Journal Articles

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

Blood Adv (2023) 7 (11): 2378–2387.

https://doi.org/10.1182/bloodadvances.2022008378

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Blood Adv (2023) 7 (6): 933–942.

https://doi.org/10.1182/bloodadvances.2022008316

Published: 2023

Includes: Supplemental data

Journal Articles

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

Sangeetha Venugopal, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Naveen Pemmaraju, Nicholas J. Short, Hussein A. Abbas, Guillermo Garcia-Manero, Marina Konopleva, Farhad Ravandi, Tapan M. Kadia

Blood Adv (2022) 6 (19): 5546–5549.

https://doi.org/10.1182/bloodadvances.2021006689

Published: 2022

Journal Articles

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

Chong Chyn Chua, Danielle Hammond, Andrew Kent, Ing Soo Tiong, Marina Y. Konopleva, Daniel A. Pollyea, Courtney D. DiNardo, Andrew H. Wei

Blood Adv (2022) 6 (13): 3879–3883.

https://doi.org/10.1182/bloodadvances.2022007083

Published: 2022

Includes: Supplemental data

Journal Articles

Outcomes of acute lymphoblastic leukemia with KMT2A ( MLL ) rearrangement: the MD Anderson experience

Guillaume Richard-Carpentier, Hagop M. Kantarjian, Guilin Tang, C. Cameron Yin, Joseph D. Khoury, Ghayas C. Issa, Fadi Haddad, Nitin Jain, Farhad Ravandi, Nicholas J. Short, Courtney D. DiNardo, Koichi Takahashi, Marina Y. Konopleva, Naval G. Daver, Tapan Kadia, Guillermo Garcia-Manero, Rebecca Garris, Susan O’Brien, Elias Jabbour

Blood Adv (2021) 5 (23): 5415–5419.

https://doi.org/10.1182/bloodadvances.2021004580

Published: 2021

Journal Articles

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Blood Adv (2021) 5 (16): 3163–3173.

https://doi.org/10.1182/bloodadvances.2020003829

Published: 2021

Journal Articles

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Lucia Masarova, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Naval G. Daver, Tapan M. Kadia, Helen T. Chifotides, Lingsha Zhou, Gautam Borthakur, Zeev Estrov, Marina Konopleva, Srdan Verstovsek

Blood Adv (2021) 5 (8): 2156–2164.

https://doi.org/10.1182/bloodadvances.2020003934

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Blood Adv (2021) 5 (8): 2173–2183.

https://doi.org/10.1182/bloodadvances.2020004173

Published: 2021

Includes: Supplemental data

Journal Articles

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Adv (2021) 5 (7): 1876–1883.

https://doi.org/10.1182/bloodadvances.2020003717

Published: 2021

Includes: Supplemental data

Journal Articles

Accurate germline RUNX1 variant interpretation and its clinical significance

Simone Feurstein, Liying Zhang, Courtney D. DiNardo

Blood Adv (2020) 4 (24): 6199–6203.

https://doi.org/10.1182/bloodadvances.2020003304

Published: 2020

Journal Articles

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

Nicholas J. Short, Hind Rafei, Naval Daver, Hyunsoo Hwang, Jing Ning, Jeffrey L. Jorgensen, Tapan M. Kadia, Courtney D. DiNardo, Sa A. Wang, Elias Jabbour, Uday Popat, Betul Oran, Jorge Cortes, Marina Konopleva, Musa Yilmaz, Ghayas C. Issa, Hagop Kantarjian, Farhad Ravandi

Blood Adv (2020) 4 (24): 6117–6126.

https://doi.org/10.1182/bloodadvances.2020002811

Published: 2020

Includes: Supplemental data

Journal Articles

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Nicholas J. Short, Guillermo Montalban-Bravo, Hyunsoo Hwang, Jing Ning, Miguel J. Franquiz, Rashmi Kanagal-Shamanna, Keyur P. Patel, Courtney D. DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Koichi Takahashi, Marina Konopleva, Naval Daver, Ghayas C. Issa, Michael Andreeff, Hagop Kantarjian, Tapan M. Kadia

Blood Adv (2020) 4 (22): 5681–5689.

https://doi.org/10.1182/bloodadvances.2020003120

Published: 2020

Includes: Supplemental data

Journal Articles

Outcome of patients with IDH1/2- mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Helen T. Chifotides, Lucia Masarova, Mansour Alfayez, Naval Daver, Yesid Alvarado, Elias Jabbour, Marina Konopleva, Hagop M. Kantarjian, Keyur P. Patel, Courtney D. DiNardo, Srdan Verstovsek

Blood Adv (2020) 4 (21): 5336–5342.

https://doi.org/10.1182/bloodadvances.2020001528

Published: 2020

Journal Articles

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1 -mutant relapsed or refractory AML

Blood Adv (2020) 4 (9): 1894–1905.

https://doi.org/10.1182/bloodadvances.2020001503

Published: 2020

Includes: Supplemental data

NARROW

Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome

Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasm

Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials

Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax

Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1 , GATA2 , and DDX41

Impact of type of induction therapy on outcomes in older adults with AML after allogeneic stem cell transplantation

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2 -mutant myelodysplastic syndrome

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

Outcomes of acute lymphoblastic leukemia with KMT2A ( MLL ) rearrangement: the MD Anderson experience

Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis

Single-center experience with venetoclax combinations in patients with newly diagnosed and relapsed AML evolving from MPNs

Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Accurate germline RUNX1 variant interpretation and its clinical significance

Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Outcome of patients with IDH1/2- mutated post–myeloproliferative neoplasm AML in the era of IDH inhibitors

Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1 -mutant relapsed or refractory AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only